Faculty Profiles - MARUYAMA, Shoichi

Papers - MARUYAMA, Shoichi

Division display 1 - 20 of about 410 ／ All the affair displays >>

Urinary Basigin/CD147 is a useful marker of acute T cell-mediated rejection in kidney transplant recipients Open Access

Futamura, K; Tsujita, M; Kosugi, T; Ryuge, A; Okada, M; Hiramitsu, T; Narumi, S; Takeda, A; Watarai, Y; Morozumi, K; Maruyama, S

RENAL FAILURE Vol. 47 ( 1 ) page： 2479574 2025.12

Urinary presepsin can efficiently detect T-cell-mediated rejection in patients who have undergone kidney transplantation

Kawazoe, T; Tanaka, A; Furuhashi, K; Hattori, K; Onogi, C; Owaki, A; Kato, A; Watanabe, Y; Koshi-Ito, E; Kato, N; Kosugi, T; Sano, Y; Ishida, S; Maruyama, S

CLINICAL AND EXPERIMENTAL NEPHROLOGY 2025.4

Ameliorative Effect of an Anti-microRNA-21 Oligonucleotide on Animal and Human Models of Cystic Kidney Disease. Open Access

Noda Y, Kato N, Sato F, Suzuki Y, Tsubota S, Kitai H, Komatsu S, Tanaka A, Sato Y, Maeda K, Furuhashi K, Ishimoto T, Kosugi T, Yamaguchi T, Nagao S, Kamiya Y, Kadomatsu K, Asanuma H, Maruyama S

Kidney360 2025.4

Recurrent localized fever caused by cryoglobulinemic vasculitis following hemodialysis: A case report

Kojima, M; Shibata, M; Tomita, S; Ueda, R; Kasai, R; Yamamoto, E; Ban, AYK; Suzuki, S; Maruyama, S

CEN CASE REPORTS Vol. 14 ( 2 ) page： 151 - 156 2025.4

MPO-ANCA-positive rapidly progressive glomerulonephritis after COVID-19 vaccination during treatment of plaque psoriasis with bimekizumab

Sugiura, T; Doke, T; Tanaka, A; Sato, Y; Maeda, K; Furuhashi, K; Kato, N; Kosugi, T; Maruyama, S

CEN CASE REPORTS Vol. 14 ( 2 ) page： 194 - 199 2025.4

Establishing Cross-Specialty Expert Consensus on the Optimal Management of Hyperkalemia in Patients With Heart Failure and Chronic Kidney Disease Open Access

Kitai Takeshi, Maruyama Shoichi, Kuwahara Koichiro, Tamura Kouichi, Kinugawa Koichiro, Kashihara Naoki

Circulation Journal Vol. 89 ( 4 ) page： 470 - 478 2025.4

Language：English Publisher：The Japanese Circulation Society

Background: Patients with both heart failure (HF) and chronic kidney disease (CKD) are often treated with renin-angiotensin-aldosterone system inhibitors (RAASi), but these drugs can cause hyperkalemia, which may lead to their reduction or discontinuation, resulting in the loss of their beneficial effects. Approaches to managing RAASi-induced hyperkalemia are discordant, so in this study we aimed to establish a cross-specialty consensus on the optimal approach to managing hyperkalemia in patients with HF and CKD.Methods and Results: The study used a modified Delphi methodology. A steering committee of Japanese cardiologists and nephrologists drafted 26 consensus statements, which were used to create a survey, distributed across Japan. A total of 250 responses were received. Consensus, defined as 75% agreement, was achieved for 21/26 (81%) statements. Respondents agreed on the importance of effective hyperkalemia management based on serum potassium levels and supported the use of potassium binders (PBs), particularly novel PBs such as sodium zirconium cyclosilicate, to treat hyperkalemia while maintaining RAASi therapy. However, when potassium levels exceed 6.0 mEq/L, reduction or discontinuation of RAASi may be considered based on individual risk factors.Conclusions: This consensus provides proposals that may help support the optimal management of RAASi-induced hyperkalemia in Japanese patients with HF and CKD. It highlights the importance of treating hyperkalemia alongside optimal RAASi therapy.

DOI： 10.1253/circj.CJ-24-0844

Real-world safety profile of eculizumab in patients with paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, or generalized myasthenia gravis: an integrated analysis of post-marketing surveillance in Japan ( vol 118, pg 419, 2023)

Nishimura, JI; Kawaguchi, T; Ito, S; Murai, H; Shimono, A; Matsuda, T; Fukamizu, Y; Akiyama, H; Hayashi, H; Nakano, T; Maruyama, S

INTERNATIONAL JOURNAL OF HEMATOLOGY Vol. 121 ( 4 ) page： 560 - 562 2025.4

Temporal changes of the life and renal prognoses of patients with rapidly progressive glomerulonephritis in Japan, 1989-2019 Open Access

Nakajima, K; Kaneko, S; Usui, J; Tsuboi, N; Sugiyama, H; Maruyama, S; Isaka, Y; Narita, I; Yamagata, K

CLINICAL AND EXPERIMENTAL NEPHROLOGY 2025.3

In vivo efficacy and safety of systemically administered serinol nucleic acid-modified antisense oligonucleotides in mouse kidney Open Access

Tsuboi, T; Hattori, K; Ishimoto, T; Imai, K; Doke, T; Hagita, J; Ariyoshi, J; Furuhashi, K; Kato, N; Ito, Y; Kamiya, Y; Asanuma, H; Maruyama, S

MOLECULAR THERAPY NUCLEIC ACIDS Vol. 36 ( 1 ) page： 102387 2025.3

A digest of the clinical practice guideline for pediatric idiopathic nephrotic syndrome 2020 updated: medical therapy

Hamada, R; Kaku, Y; Inaba, A; Kaito, H; Kimata, T; Kondo, S; Sako, M; Sato, M; Sugimoto, K; Tanaka, S; Nagaoka, Y; Nozu, K; Hashimoto, J; Miura, K; Yamamoto, M; Kawai, F; Maruyama, S; Ishikura, K

CLINICAL AND EXPERIMENTAL NEPHROLOGY 2025.3

Plasma Metabolite Profiles Between In-Center Daytime Extended-Hours and Conventional Hemodialysis Open Access

Takami, N; Okazaki, M; Ozeki, T; Imaizumi, T; Nishibori, N; Kurasawa, S; Hishida, M; Akiyama, S; Saito, R; Hirayama, A; Kasuga, H; Kaneda, F; Maruyama, S

KIDNEY360 Vol. 6 ( 3 ) page： 420 - 431 2025.3

Clinically meaningful eGFR slope as a surrogate endpoint differs across CKD stages and slope evaluation periods: the CKD-JAC study Open Access

Imaizumi, T; Komaba, H; Hamano, T; Nangaku, M; Murotani, K; Hasegawa, T; Fujii, N; Nitta, K; Isaka, Y; Wada, T; Maruyama, S; Fukagawa, M

CLINICAL KIDNEY JOURNAL Vol. 18 ( 2 ) page： sfae398 2025.2

Unexpected Hypotension in a Female Patient with Fabry Disease: Switching from Agalsidase α to β after Long-term ERT Open Access

Sugiura Takuya, Muto Reiko, Amano Tatsuaki, Kamiya Fumitaka, Sato Yuka, Maeda Kayaho, Saito Shoji, Katsuno Takayuki, Kato Noritoshi, Higashi Michiko, Numaguchi Atsushi, Matsuda Naoyuki, Sugiura Kazumitsu, Maruyama Shoichi

Internal Medicine Vol. advpub ( 0 ) 2025.2

Language：English Publisher：The Japanese Society of Internal Medicine

Fabry disease (FD) is a rare X-linked lysosomal storage disorder. Enzyme replacement therapies (ERT), such as agalsidase α and β, are available treatment options. While infusion-related reactions (IRRs) are known to occur at the initiation of ERT owing to immune responses, there is limited information on IRRs during long-term ERT. We report the case of a female patient with Fabry disease who developed unexpected hypotension after six years of stable treatment with agalsidase α, leading to a switch to agalsidase β. Continuous monitoring may be essential to identify potential IRRs in female patients with Fabry disease receiving long-term ERT.

DOI： 10.2169/internalmedicine.4685-24

Longitudinal impact of extended-hours hemodialysis with a liberalized diet on nutritional status and survival outcomes: findings from the LIBERTY cohort Open Access

Imaizumi, T; Okazaki, M; Hishida, M; Kurasawa, S; Nishibori, N; Nakamura, Y; Ishikawa, S; Suzuki, K; Takeda, Y; Otobe, Y; Kondo, T; Kaneda, F; Kaneda, H; Maruyama, S

CLINICAL AND EXPERIMENTAL NEPHROLOGY 2025.1

Association between Serum Zinc Levels and Trabecular Bone Scores among Patients Undergoing Chronic Hemodialysis

Hori, M; Takahashi, H; Kondo, C; Takeda, A; Morozumi, K; Maruyama, S

AMERICAN JOURNAL OF NEPHROLOGY page： 1 - 7 2025.1

Development and validation of an algorithm for identifying patients undergoing dialysis from patients with advanced chronic kidney disease Open Access

Imaizumi, T; Yokota, T; Funakoshi, K; Yasuda, K; Hattori, A; Morohashi, A; Kusakabe, T; Shojima, M; Nagamine, S; Nakano, T; Huang, Y; Morinaga, H; Ohta, M; Nagashima, S; Inoue, R; Nakamura, N; Ota, H; Maruyama, T; Gobara, H; Endoh, A; Ando, M; Shiratori, Y; Maruyama, S

CLINICAL AND EXPERIMENTAL NEPHROLOGY 2025.1

Bone marrow niches orchestrate stem-cell hierarchy and immune tolerance

Furuhashi, K; Kakiuchi, M; Ueda, R; Oda, H; Ummarino, S; Ebralidze, AK; Bassal, MA; Meng, C; Sato, T; Lyu, J; Han, MG; Maruyama, S; Watanabe, Y; Sawa, Y; Kato, D; Wake, H; Reizis, B; Frangos, JA; Owens, DM; Tenen, DG; Ghiran, IC; Robson, SC; Fujisaki, J

NATURE Vol. 638 ( 8049 ) page： 206 - 215 2025.1

Randomised, double-blind study to evaluate the efficacy of rituximab in the treatment of idiopathic membranous nephropathy: A clinical trial protocol. Open Access

Shimizu S, Tanaka A, Matsuyama N, Kinoshita F, Furuhashi K, Maruyama S, PRIME Study Group

PloS one Vol. 20 ( 3 ) page： e0320070 2025

Factors associated with awareness of chronic kidney disease, and impact of awareness on renal prognosis Open Access

Hattori, A; Imaizumi, T; Toda, T; Sakurai, D; Takai, N; Miki, T; Maekawa, M; Kato, S; Hagiwara, Y; Yoshida, Y; Maruyama, S

CLINICAL AND EXPERIMENTAL NEPHROLOGY 2024.12

SUrvey of renal Biopsy registry database and Anticancer dRUg therapy in Japan (SUBARU-J study) Open Access

Kuwabara, T; Miyasato, Y; Kanki, T; Mizumoto, T; Matsubara, T; Sawa, N; Sugiyama, H; Maruyama, S; Sato, H; Tsukamoto, T; Murata, T; Miyazaki, M; Imasawa, T; Mukoyama, M; Murakami, N; Jhaveri, KD; Yanagita, M; JSN Onconephrology Working Grp

CLINICAL KIDNEY JOURNAL Vol. 17 ( 12 ) page： sfae327 2024.12

　 PREV - NEXT 　

<MARUYAMA, Shoichi>

Papers - MARUYAMA, Shoichi